Last reviewed · How we verify
Secukinumab 150 milligram [Cosentyx]
Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.
Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Secukinumab 150 milligram [Cosentyx] |
|---|---|
| Also known as | Secukinumab 300 milligram [Cosentyx] |
| Sponsor | Professor Mikkel Østergaard |
| Drug class | IL-17A inhibitor (monoclonal antibody) |
| Target | IL-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
IL-17A is a pro-inflammatory cytokine produced by T cells that drives inflammation in autoimmune and inflammatory conditions. By neutralizing IL-17A, secukinumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. This mechanism is particularly effective in conditions driven by Th17 cell-mediated immunity, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Diarrhea
- Candida infection
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: